Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.51 |
| ▸ | ITGAV | P06756 | 16/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859265 | 0.95 | ITGB3 (0.46) | ITGB3ITGAVITGA2BNAMPTHTR1A | |
| SCHEMBL6854032 | 0.95 | ITGB3 (0.46) | ITGB3ITGAVITGA2BNAMPTHTR1A | |
| SCHEMBL6859241 | 0.85 | ITGB3 (0.50) | ITGB3ITGAVITGA2BROCK2NPC1 | |
| SCHEMBL6853671 | 0.83 | RORC (0.36) | ITGB3ITGAVITGA2BNPC1RAB9A | |
| SCHEMBL6860516 | 0.81 | MAPT (0.37) | ITGB3ITGAVITGA2BNPC1RAB9A | |
| SCHEMBL6860247 | 0.81 | MAPT (0.36) | ITGB3ITGAVITGA2BNPC1RAB9A | |
| SCHEMBL7705314 | 0.81 | ITGB3 (0.45) | ITGB3ITGAVITGA2BNPC1RAB9A | |
| SCHEMBL6853814 | 0.81 | ITGB3 (0.45) | ITGB3ITGAVITGA2BNPC1RAB9A | |
| SCHEMBL6859209 | 0.81 | ITGB3 (0.45) | ITGB3ITGAVITGA2BNPC1RAB9A | |
| SCHEMBL7711502 | 0.73 | ITGB3 (0.41) | ITGB3ITGAVITGA2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | claimed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | claimed |
| US-6794385-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS; OSTEOPOROSIS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2004-09-21 | — | — | US | disclosed |
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069236-A1 | New benzoxazine derivatives useful as integrin receptor antagonists | ITGB1, ITGA1, ITGB3 | ITGB3 3/4885ITGAV 15/4885ITGA2B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.